Facilitating macromolecule delivery.

We translate more than 10 years of research and applied science at Cambridge on tailoring the best nanomaterials for drug delivery applications.

Play Video

About Us

Vector's Science

We are a University of Cambridge spin out, founded on the pioneering research in engineering nanomaterials at the Department of Chemical Engineering and Biotechnology.

Vector Bioscience develops a machine-learning empowered drug delivery platform. We are dedicated to transforming oncology treatments with our cargo-agnostic technology. Our precision-targeted delivery minimizes side effects with a higher uptake and slow release. By tailoring delivery, we achieve high local concentrations of traditionally difficult-to-formulate therapeutics.

How Our Technology Work

Data

Data-driven selection of cargoes & customisation for specific cancers

Dry Lab

ML-enabled material selection

Wet Lab

Engineering of cargo and drug loading

.

Personalized & precision medicines

Data

Data-driven selection of cargoes & antibodies for specific cancers

Dry Lab

ML-enabled material selection

Wet Lab

Engineering of cargo and drug loading

.

Personalized & precision medicines

Statistics

What we’ve done so far

0 2021

EST

0 M +

non-dilutive funding

0 +y

of R&D development

why focus on drug delivery technologies in the fight against cancer?

the people behind Vector

Vector Team

D. Fairen-Jimenez

CEO and Co-Founder

Lluna Gallego

COO and Co-Founder

Jogchum Brinksma

NED and Co-founder

Dr Fatma Demir Duman

Senior Scientist

Dr Elena Avila

Programme Manager

Dr Nazeeha Ayaz

Formulation Scientist

Advisors
Industrial
Clinical
Scientific

Our Culture

We believe in pushing boundaries, embracing differences and equality, and prioritising excellence and mutual support to progress our technology and bring it to patients.

Vision

Through pioneering tomorrow’s therapies we’re “building a future where we do not fear cancer.”

Mission

With our tailored solutions we want to improve treatments for patients with higher the efficacy and less side-effects.

Pipeline

We’re committed to delivering novel treatments to rare disease patients

ML identification

Formulation & delivery

In vitro studies

In vivo studies

Clinical planning

Partner confirmation

Pancreatic cancer 01

0%

Pancreatic cancer 02

0%

Lung cancer

0%

Glioblastoma

0%

Colorectal cancer

Prostate cancer

Breast cancer

0%
0%
0%

What’s New In The Field And Our Labs

Some of our partners

Get in touch for opportunities or collaborations.

Address

Vector Bioscience Cambridge
The Hauser Forum
3, Charles Babbage Rd
CB3 0GT Cambridge
United Kingdom

Mail Address

contact@vectorbiocam.com

Scroll to Top